MedWatch

GN seeks OTC approval for flagship product

The day after the FDA released the final rule set for the imminent over-the-counter sales of hearing aids in the US, the Danish hearing aid manufacturer announced its intention of selling its flagship product on the new market.

GN Hearing wants its product, Jabra Enhance Plus, on the OTC channel in the US | Photo: GN Hearing / PR

Danish hearing aid manufacturer GN Hearing is aiming to submit its hybrid product Jabra Enhance plus for approval as an over-the-counter product with the US Food and Drug Administration (FDA), the company reported in a press release the day after the FDA revealed the long-awaited final rule set for the upcoming sales channel.

”By planning to launch Jabra Enhance Plus under the new OTC hearing aid regulation, GN intends to make this innovative hearing health solution more widely accessible. Those looking to make their first step in their hearing health journey will also now be able to choose Jabra Enhance Plus in more channels, for instance at selected Best Buy stores and online in the fall,” GN writes in statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs